A. G. Saltykova

A. G. Saltykova

Auto-generated profile, based on publicly available information

A. G. Saltykova

First Moscow State Medical University named after I.M. Sechenov of the Ministry of Health of the Russian Federation (Sechenov University)

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2022 in Epidemiology and Vaccinal Prevention
Verified
Journal Article
Open access
PDF file
NBN I Briko
N I Briko
VKVladimir A Korshunov
Vladimir A Korshunov
АМА. Я. Миндлина
А. Я. Миндлина
RPRoman Polibin 
Roman Polibin 
АША. В. Шамис
А. В. Шамис
АСА. Г. Салтыкова
А. Г. Салтыкова
Роль образовательного компонента в формировании приверженности населения к вакцинации против пневмококковой инфекции

14 January 2025 in Epidemiology and Vaccinal Prevention
Verified
Journal Article
Open access
PDF file
RPRoman Polibin 
Roman Polibin 
TST. S. Saltykova
T. S. Saltykova
АPА. А. Pozdnyakov
А. А. Pozdnyakov
VKVladimir A Korshunov
Vladimir A Korshunov
ASA. G. Saltykova
A. G. Saltykova
NBN. I. Briko
N. I. Briko
Relevance. A distinctive feature of the influenza is the risk of severe complications, including cardiovascular (myocarditis or pericarditis) and nervous (encephalitis, meningoencephalitis and arachnoiditis) systems. Vaccination against influenza can significantly reduce the risk of disease, including complications and deaths.The aim of our study was to evaluate the epidemiological effectiveness of a quadrivalent inactivated split influenza vaccine in the 2023 –2024 season.Materials and methods. The study investigated the effectiveness of the tetravalent inactivated split vaccine Ultrix Quadri®. Vaccination data were collected in the regions of the Russian Federation as of January 1, 2024, in which a statistically significant amount of Ultrix Quadri® vaccine was used. The work was carried out using methods of variational statistics. The indicators of relative and attributive risks were evaluated, the Cochrane-Mantel-Hensel approach was applied, taking into account the assessment of heterogeneity of the results, and the effectiveness of the vaccine was evaluated.Results. The study showed that the risk of getting the flu among those vaccinated with Ultrix Quadri® vaccine was 122 (88-170) times lower than in those not vaccinated, which indicates the high epidemiological effectiveness of the vaccine. Cases of influenza among those vaccinated were observed in December 2023 - January 2024, that is, at the beginning of the epidemic season, during the period of the greatest rise in morbidity. At the same time, in absolute terms, their number was minimal. (414 cases out of 9.7 million vaccinated). From February to June 2024, the incidence of influenza among those vaccinated with the studied vaccine (with the exception of isolated cases) was not recorded.Conclusion. The conducted study demonstrated the high real epidemiological effectiveness of the Ultrix Quadri® vaccine during the epidemic season of influenza and ORI 2023/2024.